Evidence map›Paper›PMID 31605289›Full record

ArticleJournal of gastrointestinal cancer2020

Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.

Aslam R Syed, Neil M Carleton, Zachary Horne, Annika Dhawan, Gurneet Bedi, Gursimran Kochhar, Suzanne Morrissey, Harry Williams, Donald Atkinson, Suzanne Schiffman and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Effect of travel distance on utilization of ancillary services among patients with pancreatic ductal adenocarcinoma: A single institution study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Aslam R SyedDivision of Gastroenterology, Allegheny Health Network, 1307 Federal Street, Pittsburgh, PA, 15212, USA.
Neil M CarletonDivision of Gastroenterology, Allegheny Health Network, 1307 Federal Street, Pittsburgh, PA, 15212, USA.
Zachary HorneDepartment of Radiation Oncology, Allegheny Health Network, Pittsburgh, PA, USA.
Annika DhawanDivision of Gastroenterology, Allegheny Health Network, 1307 Federal Street, Pittsburgh, PA, 15212, USA.
Gurneet BediDivision of Gastroenterology, Allegheny Health Network, 1307 Federal Street, Pittsburgh, PA, 15212, USA.
Gursimran KochharDivision of Gastroenterology, Allegheny Health Network, 1307 Federal Street, Pittsburgh, PA, 15212, USA.
Suzanne MorrisseyDivision of Gastroenterology, Allegheny Health Network, 1307 Federal Street, Pittsburgh, PA, 15212, USA.
Harry WilliamsDepartment of Surgery, Allegheny Health Network, Pittsburgh, PA, USA.
Donald AtkinsonDepartment of Surgery, Allegheny Health Network, Pittsburgh, PA, USA.
Suzanne SchiffmanDepartment of Surgery, Allegheny Health Network, Pittsburgh, PA, USA.
Dulabh MongaDepartment of Hematology/Oncology, Allegheny Health Network, Pittsburgh, PA, USA.
Anthony LupetinDepartment of Radiology, Allegheny Health Network, Pittsburgh, PA, USA.
Alexander KirichenkoDepartment of Radiation Oncology, Allegheny Health Network, Pittsburgh, PA, USA.
Marcia MitreDivision of Gastroenterology, Allegheny Health Network, 1307 Federal Street, Pittsburgh, PA, 15212, USA.
Manish DhawanDivision of Gastroenterology, Allegheny Health Network, 1307 Federal Street, Pittsburgh, PA, 15212, USA.
Abhijit KulkarniDivision of Gastroenterology, Allegheny Health Network, 1307 Federal Street, Pittsburgh, PA, 15212, USA.
Shyam ThakkarDivision of Gastroenterology, Allegheny Health Network, 1307 Federal Street, Pittsburgh, PA, 15212, USA. Shyam.Thakkar@ahn.org.
Allegheny Health Network · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDespite advances in various treatment modalities, surgical resection for pancreatic ductal adenocarcinoma (PDA) remains the only curative treatment. Data remains limited regarding survival rates for resectable PDA when managed by a multidisciplinary pancreas conference (MDPC). The aim of this study is to assess survival rates, identify significant predictors of mortality, and assess the benefits of adjuvant chemotherapy for resectable PDA following presentation at a MDPC.

methodsAll patients presented from April 2013 to August 2016 with resectable PDA were discussed at a MDPC at a tertiary care center and were followed prospectively until November 2017. Survival analysis was performed using Kaplan-Meier for age, tumor size, tumor differentiation, T-stage, lymph node status, and completion of adjuvant chemotherapy cycles. Independent predictors of survival were determined using multivariate Cox regression modeling.

resultsAfter MDPC consensus and exclusions, total of 64 patients underwent successful surgery. Amongst this cohort, 1-, 2-, and 3-year survival was 78.13%, 46.30%, and 27.27%, respectively. A total of 37 patients (58%) initiated and 16 patients (25%) finished chemotherapy following surgery. Log-rank analysis revealed that tumor size, age, surgical margins, lymph node status, and number of adjuvant chemotherapy cycles received significantly influenced post-operative survival. Tumor size (p < 0.001), lymph node status (p = 0.035), and number of adjuvant chemotherapy cycles (p = 0.041) remained significant after multivariate Cox regression model.

conclusionsOur results suggest that patients with PDA with tumor size > 50 mm and/or lymph node involvement have poor outcomes despite being surgically resectable. Successful completion of adjuvant chemotherapy has better survival outcomes as compared with incomplete or no adjuvant chemotherapy. The role of alternative management such as down-staging with neoadjuvant therapy should be considered.

Indexed as

PancreatectomyAgedAge FactorsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedPancreasPancreatic NeoplasmsPatient Care TeamAdjuvant chemotherapyMultidisciplinary pancreatic cancer conferenceNeoadjuvant therapyResectable pancreatic cancerSurvival outcomes

Identifiers

PMID31605289
OpenAlexW2980180917

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.